Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: Pharmacological rationale and clinical response

Pediatric Blood and Cancer

Volumn 54, Issue 1, 2010, Pages 55-61

  Donfrancesco, Alberto ^a   De Ioris, Maria Antonietta ^a   McDowell, Heather Prudence ^b   De Pasquale, Maria Debora ^a   Ilari, Ilaria ^a   Jenkner, Alessandro ^a   Castellano, Aurora ^a   Cialfi, Samantha ^c   De Laurentis, Clementina ^a   Dominici, Carlo ^a,c,d  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d School of Reproductive and Developmental Medicine   (United Kingdom)

Author keywords

EGFR; Neuroblastoma; Oral chemotherapy; Targeted therapy

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; GEFITINIB; TOPOTECAN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LOBAR PNEUMONIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROBLASTOMA CELL; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SKIN TOXICITY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE; AGED; CANCER STAGING; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PILOT STUDY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PILOT PROJECTS; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALVAGE THERAPY; SURVIVAL RATE; TOPOTECAN; TREATMENT OUTCOME;

EID: 73349101900     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22219     Document Type: Article

References (43)

1. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-292.
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
3. Shintani S, Li C, Mihara M, et al. Gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 2003;201:149-155.
4. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 2003;107:1030-1037.
5. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-930.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-2246.
7. McDowell HP, Meco D, Riccardi A, et al. Imatinib mesylate potentiates topotecan antitumour activity in rhabdomyosarcoma preclinical models. Int J Cancer 2007;120:1141-1149.
8. Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 2006;46:381-410.
9. Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-1495.
10. Bowers DC, Aquino VM, Leavey PJ, et al. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatr Blood Cancer 2004;42:93-98.
11. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
13. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 2002;277:47980-47990.
14. Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-1495.
15. Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-425.
16. International Common Toxicity Criteria Version 3 (CTC.3). Available fromURL: http://www.fda.gov/cder/cancer/toxicityframe. htm.
17. Brodeur GM, Pritchard J, Berthold F, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993;11:1466-1477.
18. Donfrancesco A, Jenkner A, De Ioris MA, et al. Prolonged response to oral gefitinib, cyclophophamide and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: A case report. J Pediatr Hematol Oncol 2007;29:799-803.
19. Ho R, Minturn JE, Hishiki T, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005;65:9868-9875.
20. Castel V, Canete C, Melero T, et al. Results of the cooperative protocol (N-IIII-95) for metastatic relapses and refractory neuroblastoma. Med Pediatr Oncol 2000;35:1363-1369.
21. Campbell LA, Seeger RC, Harris RE, et al. Escalating dose of continuos infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 1993;11:623-629.
22. Alvarado CS, Kretschmar C, Joshi VV, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: A POG phase II study. J Pediatr Hematol Oncol 1997;19:62-67.
23. Simon T, Langler A, Berthold F, et al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: Result of phase II trial. J Pediatr Hematol Oncol 2007;29:101-106.
24. Rubie H, Chisholm J, Defachelles AS, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma:A joint Societé Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-NewAgents Group Study. J Clin Oncol 2006;24:5259-5264.
25. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-5754.
26. Tysnes BB, Haugland HK, Bjerkvig R. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Invasion Metastasis 1997;17:270-280.
27. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high grade nonbrainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-1792.
28. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-6970.
29. Tabori U, Rienstein S, Dromi Y, et al. Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas. J Neurosurg 2005;103:357-361.
30. Ye D, Maitra A, Timmons CF, et al. The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma. J Pediatr Hematol Oncol 2003;25:459-466.
31. Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006;24:816-822.
32. Freeman BB III, Daw NC, Geyer JR, et al. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 2006;24:310-317.
33. Stewart CF, Leggas M, Schuetz JD, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 2004;64:7491-7499.
34. Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 2004;22:829-837.
35. Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: A retrospective analysis. Pediatr Hematol Oncol 2003;25:601-605.
36. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 2006;24:64-69.
37. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346.
38. Ciardiello F, Troiani T, Caputo F, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006;94:1604-1609.
39. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-1619.
40. LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 2003;9:2040-2048.
41. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-142.
42. Cohen MH,Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
43. Daw NC, Furman WL, Stewart CF, et al. A phase I trial and pharmacokinetic study of gefitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2005;23:6172-6180.